This is a multi-center (North-America), randomized, double-blind, placebo-controlled,
wait-list, interventional, preventive trial of guselkumab in high-risk psoriasis patients
compared to non-biologic standard of care.
The primary objective of our proposed trial will be to test the hypothesis that a prolonged,
unresolved skin inflammation coupled with musculoskeletal power-doppler ultrasound (MSKPDUS)
abnormalities driven by IL-23 increase the risk for transition into PsA and that an
intervention that targets one of these pivotal molecules (i.e., Guselkumab) will:
1. Diminish MSKPDUS findings at 24 weeks, and
2. Significantly reduce or prevent the emergence of synovio-enthesial phenotype at year 2.